Free Trial

Genenta Science (GNTA) Competitors

Genenta Science logo
$3.82 +0.00 (+0.13%)
As of 07/25/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GNTA vs. AVTE, DBVT, ALLO, ZYBT, ACB, SCPH, INZY, VOR, ANNX, and AARD

Should you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Aerovate Therapeutics (AVTE), DBV Technologies (DBVT), Allogene Therapeutics (ALLO), Zhengye Biotechnology (ZYBT), Aurora Cannabis (ACB), scPharmaceuticals (SCPH), Inozyme Pharma (INZY), Vor Biopharma (VOR), Annexon (ANNX), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry.

Genenta Science vs. Its Competitors

Genenta Science (NASDAQ:GNTA) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

15.1% of Genenta Science shares are held by institutional investors. 29.0% of Genenta Science shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$9.64MN/AN/A
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.90

In the previous week, Genenta Science had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Genenta Science and 0 mentions for Aerovate Therapeutics. Genenta Science's average media sentiment score of 1.89 beat Aerovate Therapeutics' score of 0.00 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Very Positive
Aerovate Therapeutics Neutral

Genenta Science has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Genenta Science's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
Aerovate Therapeutics N/A -90.19%-77.47%

Genenta Science currently has a consensus target price of $25.00, suggesting a potential upside of 556.34%. Given Genenta Science's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genenta Science is more favorable than Aerovate Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Genenta Science beats Aerovate Therapeutics on 10 of the 11 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

MetricGenenta ScienceMED IndustryMedical SectorNASDAQ Exchange
Market Cap$69.68M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E RatioN/A21.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book5.158.378.665.87
Net Income-$9.64M-$55.19M$3.25B$258.55M
7 Day Performance1.03%5.88%4.22%3.73%
1 Month Performance25.05%17.33%10.51%11.75%
1 Year Performance-9.09%4.42%34.40%18.03%

Genenta Science Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
2.7341 of 5 stars
$3.81
0.0%
$25.00
+556.3%
-9.5%$69.68MN/A0.007
AVTE
Aerovate Therapeutics
N/A$9.47
-0.4%
N/A-87.6%$274.49MN/A-3.1720High Trading Volume
DBVT
DBV Technologies
3.9053 of 5 stars
$9.50
-5.0%
$14.75
+55.3%
+85.8%$273.90MN/A-1.9380Upcoming Earnings
Gap Up
ALLO
Allogene Therapeutics
3.2649 of 5 stars
$1.32
+5.6%
$8.44
+539.7%
-48.5%$273.41M$20K-1.07310Positive News
ZYBT
Zhengye Biotechnology
N/A$5.69
flat
N/AN/A$268.38M$25.53M0.00278Positive News
Gap Up
ACB
Aurora Cannabis
0.2807 of 5 stars
$4.70
+3.8%
N/A-16.4%$264.36M$343.29M42.731,130
SCPH
scPharmaceuticals
4.3806 of 5 stars
$5.13
+3.8%
$14.00
+172.9%
+12.4%$260.79M$41.98M-2.6930News Coverage
INZY
Inozyme Pharma
2.7939 of 5 stars
$4.00
flat
$11.75
+193.8%
N/A$258.25MN/A-2.3750
VOR
Vor Biopharma
3.8809 of 5 stars
$2.05
-7.2%
$5.63
+174.6%
+131.2%$256.17MN/A-1.24140
ANNX
Annexon
2.4431 of 5 stars
$2.47
+6.5%
$12.50
+406.1%
-59.4%$254.54MN/A-2.0960
AARD
Aardvark Therapeutics
N/A$12.00
+3.3%
$33.00
+175.0%
N/A$252.11MN/A0.0018

Related Companies and Tools


This page (NASDAQ:GNTA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners